QMH-CML-001 = Cessation of TKI in CML [Hong Kong]
Type of study
Treatment discontinuation trial
Current status
Unknown
Study title
QMH-CML-001 = Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic Phase Chronic Myelogenous Leukaemia
Scientific title
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia Who Achieve Stable Deep Molecular Response (ClinicalTrials.gov NCT03131986)
What is the purpose of the study
International clinical trials have demonstrated that about 40-60% of CML patients who achieved deep molecular response on TKI manage to remain in sustained treatment-free remission after stopping treatment. Experience of discontinuing TKI treatment is lacking in Hong Kong.
The objective of this single-arm study is to collect local experience with TKI discontinuation in patients with CML in chronic phase who are treated with TKIs and remain in stable deep molecular response for at least two years. Patients who stop TKI treatment will be closely monitored and treatment outcomes will be reassessed.
Key inclusion criteria
This study includes male or female patients who:
– are at least 18 years old
– have been diagnosed with chronic myeloid leukemia in chronic phase
– have been treated with a tyrosine kinase inhibitor (TKI) in first line, or in second line due to intolerance of another first-line TKI
– have been on treatment with the same TKI for at least 3 years and had deep molecular response (MR4.5) for at least 2 years
Key exclusion criteria
Where can I find additional information
Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health
Study sponsor
The University of Hong Kong
Scientific lead / contact
Professor Yok-lam Kwong
The University of Hong Kong
Principal investigator
Contact: Yuk Man Cheung, MBBS(HK)
Study centers / principal investigators
Hong Kong
Yuk Man Cheung, MBBS(HK)
Queen Mary Hospital, Hong Kong